Prescription drug monitoring programs (PDMPs) are tools that states can use to fight prescription opioid misuse within their jurisdiction. However, because PDMPs make prescription opioids more difficult to access, these programs may have the unintended consequence of increasing deaths related to illicit opioids.
Methods
This study uses fixed effects models to estimate how PDMP regulatory strength is associated with both prescription opioid- and heroin-related deaths between 1999 and 2016. PDMP regulatory strength is measured by creating a score using multiple correspondence analysis (MCA). Additional models replace the MCA score with a binary indicator for the presence of one particular regulation requiring physicians to access the system before writing opioid prescriptions.
Results
Results show that continuous measures of PDMP strength are not generally associated with prescription opioid- or heroin-related death rates. Yet, one model does show that PDMP scores are positively associated with the heroin-related death rate. The models using the binary mandatory access variable show a strong positive association with both prescription opioid and heroin deaths.
Conclusions
This study supports the theory that more stringent state PDMPs are associated with higher rates of heroin-related deaths, potentially due to decreases in prescription opioid availability.
FinkleaK, SaccoLN, BagalmanE.Prescription Drug Monitoring Programs. Washington, DC: Congressional Research Service; 2014. CRS Report 7-5700.
3.
DunnKM, SaundersKW, RutterCM, . Opioid prescriptions for chronic pain and overdose. Ann Intern Med.2010;152(2):85–92.
4.
EdlundMJ, SteffickD, HudsonT, HarrisKM, SullivanM.Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain2007;129(3):355–362.
5.
MillerM, BarberCW, LeathermanS, . Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. Jama Int Med.2015;175:608–615.
6.
PeirceGL, SmithMJ, AbateMA, HalversonJ.Doctor and pharmacy shopping for controlled substances. Medical Care.2012;50(6):494–500.
7.
DasguptaN, CreppageK, AustinA, RingwaltC, SanfordC, ProescholdbellSK.Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend.2014;45:238–241.
8.
MaxwellJC.The pain reliever and heroin epidemic in the United States: shifting winds in the perfect storm. J Addictive Diseases.2015;34(2–3):127–140.
9.
AliMM, DowdWN, ClassenT, MutterR, NovakSP.Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey on Drug Use and Health. Addict Behav.2017;69:65–77.
10.
BranhamDK.Time-series analysis of the impact of prescription drug monitoring programs on heroin treatment admissions. Subst Use Misuse.2018;53:694–701.
11.
FaryarKA, FreemanCL, PersaudAK, . The effects of Kentucky's comprehensive opioid legislation on patients presenting with prescription opioid or heroin abuse to one urban emergency department. J Emerg Med.2017;53(6):805–814.
12.
VictorGA, WalkerR, ColeJ, LoganTK.Opioid analgesics and heroin: examining drug misuse trends among a sample of drug treatment clients in Kentucky. Int J Drug Policy.2017;46:1–6.
13.
JonesCM.Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002-2004 and 2008-2010. Drug Alcohol Depend.2013;132(1–2):95–100.
14.
LankenauSE, TetiM, SilvaK, BloomJJ, HarocoposA, TreeseM.Initiation into prescription opioid misuse among young injection drug users. Int J Drug Policy.2012;23(1):37–44.
15.
MarsSG, BourgoisP, KarandinosG, MonteroF, CiccaroneD.Every ‘never’ I ever said came true”: transitions from opioid pills to heroin injecting. Int J Drug Policy.2014;25(2):257–266.
PolliniRA, Banta-GreenCJ, Cuevas-MotaJ, MetznerM, TeshaleE, GarfeinRS.Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehab.2011;2(1):173–180.
18.
CiceroTJ, KasperZA, EllisMS.Increased use of heroin as an initiating opioid of abuse: further considerations and policy implications. Addict Behav.2018;87:267–271.
19.
BrownR, RileyMR, UlrichL, . Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity. Drug Alcohol Depend.2017;178:348–354.
20.
MeinhoferA.Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse. Am J Health Econ.2018;4(4):504–526.
21.
PaulozziLJ, KilbourneEM, DesaiHA.Prescription drug monitoring programs and death rates from drug overdose. Pain Med.2011;12(5):747–754.
22.
PatrickSW, FryCE, JonesTF, BuntinMB.Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs.2016;35(7):1324–1332.
23.
PardoB.Do more robust prescription drug monitoring programs reduce prescription opioid overdose?Addiction2017;112(10):1773–1783.
24.
HorwitzJ, DavisCS, McClellandLS, FordonRS, MearaE.The Problem of Data Quality in Analysis of Opioid Regulation: The Case of Prescription Drug Monitoring Programs. Cambridge, MA: National Bureau of Economic Research; 2018. NBER working paper #24947.
25.
BuchmuellerTC, CareyC.The effect of prescription drug monitoring programs on opioid utilization in Medicare. American Economic Journal: Economic Policy.2018;10(1):77–112.
26.
ComptonWM, BoyleM, WargoE.Prescription opioid abuse: problems and responses. Prevent Med.2015;80:5–9.
27.
HewlettL, WermelingDP.Survey of naloxone legal status in opioid overdose prevention and treatment. J Opioid Manage.2013;9(5):369–377.
28.
OkieS.A flood of opioids, a rising tide of deaths. N Engl J Med.2010;363(21):1981–1985.
29.
PowellD, PaculaRL, JacobsonM.Do medical marijuana laws reduce addictions and deaths related to pain killers?J Health Econ.2018;58:29–42.
30.
AndersonRN, RosenbergHM.Age standardization of death rates: implementation of the year 2000 standard. Nat Vital Stat Rep.1988;47:1–20.
31.
BohnertAS, ValensteinM, BairMJ, . Association between opioid prescribing patterns and opioid overdose-related deaths. J Am Med Assoc.2011;305(13):1315–1321.
JoyntM, TrainMK, RobbinsBW, HaltermanJS, CaiolaE, FortunaRJ.The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States. J Gen Intern Med.2013;28(12):1604–1610.
34.
KohnJL.What is health? A multiple correspondence health index. Eastern Econ J.2012;38(2):223–250.
35.
CortinovisI, VellaV, NdikuJ.Construction of a socio-economic index to facilitate analysis of health data in developing countries. Social Sci Med.2012;36(8):1087–1097.
36.
EzzrariA, VermeP.A Multiple Correspondence Analysis Approach to the Measurement of Multidimensional Poverty in Morocco, 2001-2007. Washington, DC: World Bank; 2012. World Bank Policy Research Working Paper #6087.
37.
AbdiH, ValentinD.Multiple correspondence analysis. In: SalkindN, ed. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: SAGE Publications Inc.; 2006:1–13
38.
HillMO, SmithA.Principal component analysis of taxonomic data with multi-state discrete characters. Taxon1976;25(2–3):249–255.
39.
KolenikovS, AngelesG.Socioeconomic status measurement with discrete proxy variables is principal component analysis a reliable answer?Rev Income Wealth.2009;55(1):128–165.
40.
SourialN, WolfsonC, ZhuB, . Correspondence analysis is a useful tool to uncover the relationships among categorical variables. J Clin Epidemiol.2010;63(6):638–646.
41.
SeplakiCL, AgreeEM, WeissCO, SzantonSL, Bandeen-RocheK, FriedLP.Assistive devices in context: cross-sectional association between challenges in the home environment and use of assistive devices for mobility. The Gerontol.2014;54(4):651–660.
42.
DowellD, ZhangK, NoonanRK, HockenberryJM.Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Affairs.2016;35(10):1876–1883.
43.
GrecuAM, DaveDM, SafferH.Mandatory access prescription drug monitoring programs and prescription drug abuse. J Pol Anal Manage.2019;38(1):181–209.
44.
RasubalaL, PernapatiL, ValasquezX, BurkJ, RenYF.Impact of a mandatory prescription drug monitoring program on prescription of opioid analgesics by dentists. PLoS One.2015;10:110.
45.
WinstanleyEL, ZhangY, MashniR, . Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug Alcohol Depend.2018;188:169–174.
46.
LinDH, LucasE, MurimiIB, . Physician attitudes and experiences with Maryland's prescription drug monitoring program. Addiction2017;112(2):311–319.
47.
RutkowL, TurnerL, LucasE, HwangC, AlexanderGC.Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Affairs.2015;34(3):484–492.
48.
InciardiJA, SurrattHL, CiceroTJ, BeardRA.Prescription opioid abuse and diversion in an urban community. Pain Med.2009;10(3):537–548.
49.
DavisWR, JohnsonBD.Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend.2008;92(1–3):267–276.
50.
CiccaroneD.Editorial for “U.S. heroin in transition: supply changes, fentanyl adulteration and consequences” IJDP special section. Int J Drug Policy.2017;46:107–111.
51.
FrankRG, PollackHA.Addressing the fentanyl threat to public health. N Engl J Med.2017;376(7):605–607.
